Our People


Chairman of the Board: Patrick Grier
CEO/Director: Dr. Joachim Fluhrer MBBS, FACNEM
Director:  Michael Hall
Director: John Bacon
Director: Jeff Banks


Research Director: Prof. Basil Roufogalis

Advisory committe members:
Prof. Katharina Pachmann
Prof Stephen Clarke
A/Prof David Bell
Prof. Rik Thompson
A/Prof Mary Bebawy


Joachim Fluhrer, Medical Director and CEO
A/Prof. David Bell, Medical Advisor
John Bacon,  Business Development
Gail Lucchessic Office Administration, Logistics
Gabrielle Hayes Office Administration, Communications
Johanna Fluhrer Medical Writer, Media and Communications.

Dr. Joachim Fluhrer

Dr. Joachim Fluhrer

Dr. Joachim Fluhrer
Medical Director, Genostics

Dr Fluhrer is an Integrative Medicine Practitioner combining General Practice with evidence based Gene Diagnosis and Complementary Medicine.

Dr Fluhrer is dedicated to helping health practitioners create effective, personalised treatment strategies for their patients.

Dr Fluhrer's interest and research into the utility of CTCs in clinical practice has spanned over a decade. He brings this vast knowledge and expertise to his role as Medical Director of Genostics. In this role, Dr Fluhrer analyses complex CTC test data and prepares the Genostics test report. He also educates health practitioners on CTC science and testing, molecular technology and advances in personalised cancer testing. 

Please note Genostics does not engage in medical practice.

For more information, please visit Dr. Fluhrer's website.

Prof. Katherina Pachmann

Prof. Katherina Pachmann

Prof. Katharina Pachmann
Director, Laborpraxis Pachmann

Professor Pachmann has concentrated her research career on the detection, identification, and treatment of cancer cells in the peripheral blood. Professor Pachmann has worked in cell research internationally in academically and scientifically acclaimed centres such as Karolinka Insitute Stockholm, Sweden; Institute of Hematology,GSF Munich, Germany; MD Anderson Cancer Centre Houston, Texas.

Presently Professor Pachmann has her laboratory at the Klinik fur Innere Medizin II Fredrich-Schiller Universitat in Germany, where she holds Professorship Experimental Hematology and Oncology. Professor Pachmann has numerous publications in world renowned journals of Hematology, Clinical Oncology, Surgical Oncology and Cancer Research.

Associate Prof. David Bell

Associate Prof. David Bell

Associate Prof. David Bell, Medical Advisor to Genostics

Assoiciate Professor David Bell is currently Senior Staff Specialist, Medical Oncology at Royal North Shore Hospital, with responsibility for the Medical Oncology Unit. Malignancies include breast, lung, colon and rectum, testicular, sarcoma, renal, melanoma, lymphoma, head and neck and brain.

He is a Visiting Medical Oncologist at North Shore Private Hospital, Manly Waters Private and Armidale Base Hospital.

Dr Bell is also Clinical Senior Lecturer in Medicine at the University of Sydney and has conducted both clinical and laboratory research work which has been widely published. He is also Associate Professor in Rural medicine at the University of New England. He is principle researcher in numerous studies covering aspects of lung, breast, ovarian, soft tissue, skin and renal cancer as well as investigations of multidrug resistance and drugs of potential patient benefit.

Dr Bell has been an invited speaker at numerous national and international forums including the USA, Canada, Hong Kong, Singapore, France and Germany.

In his role as Medical Advisor with Genostics, Associate Prof. David Bell is recognised as a company expert in the clinical utility of Circulating Tumour Cell testing in personalised cancer management. Ongoing liaison with the Medical Director of Genostics ensures that significant scientific and clinical developments in the field are identified and monitored.

Gabrielle Hayes

Gabrielle Hayes

Gail Luchesic &
Gabrielle Hayes


Office hours are Monday to Friday, 9am-4:30pm. Feel free to call Gabrielle on 1300 282 480, or email her at You are welcome to connect with us via Facebook and social media. We're looking forwards to staying in touch.